Document is current
Any future updates will be listed below
-
Authors
Wang, Jun
Yu, Xufen
Gong, Weida
Liu, Xijuan
Park, Kwang-Su
Ma, Anqi
Tsai, Yi-Hsuan http://orcid.org/0000-0003-2107-4300
Shen, Yudao
Onikubo, Takashi
Pi, Wen-Chieh
Allison, David F.
Liu, Jing
Chen, Wei-Yi
Cai, Ling
Roeder, Robert G.
Jin, Jian http://orcid.org/0000-0002-2387-3862
Wang, Gang Greg http://orcid.org/0000-0002-7210-9940
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA218600, R01CA211336)
- License Information
-
More Information
Article History
Received: 29 July 2021
Accepted: 14 January 2022
First Online: 24 February 2022
Competing interests
: Icahn School of Medicine at Mount Sinai filed a patent application (WO 2018/081530 A1) covering EZH2 degraders that lists J.J. and A.M. as inventors. The Jin Laboratory received research funds from Celgene Corporation, Levo Therapeutics, Cullgen, Inc. and Cullinan Oncology. J.J. is a co-founder, scientific advisory board member and equity shareholder in Cullgen Inc., and is a consultant for Cullgen Inc., EpiCypher Inc. and Accent Therapeutics Inc. The remaining authors declare no competing interests.
